 In May 2017, the Government of India decided to include pneumococcal conjugate vaccine in its Universal Immunization Programme.In the United States, a heptavalent pneumococcal conjugate vaccine (PCV 7) (e.g.Prevnar, called Prevenar in some countries) was recommended for all children aged 2–23 months and for at-risk children aged 24–59 months in 2000.